S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
Log in

NASDAQ:RGEN - Repligen Stock Price, Forecast & News

$100.85
-0.16 (-0.16 %)
(As of 01/22/2020 04:00 PM ET)
Today's Range
$100.67
Now: $100.85
$102.76
50-Day Range
$88.39
MA: $93.77
$101.01
52-Week Range
$52.87
Now: $100.85
$102.76
Volume235,107 shs
Average Volume324,072 shs
Market Capitalization$5.25 billion
P/E Ratio205.82
Dividend YieldN/A
Beta1.12
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RGEN
CUSIP75991610
Phone781-250-0111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$194.03 million
Cash Flow$1.12 per share
Book Value$14.03 per share

Profitability

Net Income$16.62 million

Miscellaneous

Employees548
Market Cap$5.25 billion
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive RGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.


Repligen (NASDAQ:RGEN) Frequently Asked Questions

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) released its quarterly earnings data on Thursday, October, 31st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.19 by $0.07. The biotechnology company had revenue of $69.45 million for the quarter, compared to analysts' expectations of $66.10 million. Repligen had a net margin of 9.28% and a return on equity of 6.50%. The business's revenue was up 40.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.20 EPS. View Repligen's Earnings History.

When is Repligen's next earnings date?

Repligen is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Repligen.

What guidance has Repligen issued on next quarter's earnings?

Repligen updated its FY19 earnings guidance on Thursday, October, 31st. The company provided earnings per share guidance of $1.00-1.04 for the period, compared to the Thomson Reuters consensus estimate of $0.97. The company issued revenue guidance of $267-270 million, compared to the consensus revenue estimate of $266.06 million.

What price target have analysts set for RGEN?

7 equities research analysts have issued 12-month price objectives for Repligen's stock. Their forecasts range from $100.00 to $110.00. On average, they expect Repligen's share price to reach $106.14 in the next year. This suggests a possible upside of 5.2% from the stock's current price. View Analyst Price Targets for Repligen.

What is the consensus analysts' recommendation for Repligen?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Repligen.

What are Wall Street analysts saying about Repligen stock?

Here are some recent quotes from research analysts about Repligen stock:
  • 1. HC Wainwright analysts commented, "We utilize a discounted cash flow (DCF)-driven analysis approach to value Repligen shares. Our assessment yields an enterprise value of roughly $5.5B. We utilize a roughly 7.5% discount rate (vs. the previous 9%) and 26% effective tax rate. This yields a market value of the firm of $5.7B, assuming roughly $527M in cash as of mid-2020, which reflects the proceeds from the $287.5M convertible note offering completed in July 2019. Given the projected 52M shares outstanding as of mid-2020, this yields a price objective of roughly $110 per share." (8/12/2019)
  • 2. According to Zacks Investment Research, "Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development. " (8/7/2019)

Has Repligen been receiving favorable news coverage?

Headlines about RGEN stock have trended very negative on Wednesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Repligen earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View News Stories for Repligen.

Are investors shorting Repligen?

Repligen saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 2,420,000 shares, a decline of 29.4% from the December 15th total of 3,430,000 shares. Based on an average daily trading volume, of 397,600 shares, the short-interest ratio is currently 6.1 days. Currently, 5.1% of the company's shares are sold short. View Repligen's Current Options Chain.

Who are some of Repligen's key competitors?

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Veeva Systems (VEEV), Xilinx (XLNX), salesforce.com (CRM), Corcept Therapeutics (CORT), Micron Technology (MU), Fortinet (FTNT) and Okta (OKTA).

Who are Repligen's key executives?

Repligen's management team includes the folowing people:
  • Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 55)
  • Mr. Jon K. Snodgres, CFO & Sec. (Age 53)
  • Mr. Steve Curran, VP of Global Operations
  • Ms. Sondra S. Newman, Sr. Director of Investor Relations
  • Mr. Stephen Tingley, VP of Sales

Who are Repligen's major shareholders?

Repligen's stock is owned by many different of retail and institutional investors. Top institutional investors include Summit Creek Advisors LLC (0.16%), Assenagon Asset Management S.A. (0.02%), Louisiana State Employees Retirement System (0.02%), State of Alaska Department of Revenue (0.01%), NewSquare Capital LLC (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Repligen stock include Anthony Hunt, Glenn L Md Cooper, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.

Which institutional investors are selling Repligen stock?

RGEN stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Summit Creek Advisors LLC. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Glenn L Md Cooper, Jon Snodgres, Karen A Dawes and Ralf Kuriyel. View Insider Buying and Selling for Repligen.

Which institutional investors are buying Repligen stock?

RGEN stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., NewSquare Capital LLC, Janney Montgomery Scott LLC, Ballentine Partners LLC, Allred Capital Management LLC, Zurcher Kantonalbank Zurich Cantonalbank , Lenox Wealth Advisors LLC and Louisiana State Employees Retirement System. View Insider Buying and Selling for Repligen.

How do I buy shares of Repligen?

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $100.85.

How big of a company is Repligen?

Repligen has a market capitalization of $5.25 billion and generates $194.03 million in revenue each year. The biotechnology company earns $16.62 million in net income (profit) each year or $0.73 on an earnings per share basis. Repligen employs 548 workers across the globe.View Additional Information About Repligen.

What is Repligen's official website?

The official website for Repligen is http://www.repligen.com/.

How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]


MarketBeat Community Rating for Repligen (NASDAQ RGEN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  313 (Vote Outperform)
Underperform Votes:  294 (Vote Underperform)
Total Votes:  607
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: Inverted Yield Curve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel